Cladribine

Generic Name: Cladribine

Brand Names: Litak, Mavenclad

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂ClN_₅O_₃

CAS Number: 4291-63-8

Unique Ingredient Identifier: 47M74X9YT5

Background: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

Indication: For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Associated Therapies: -

Clinical Trials

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Phase 2

Active, not recruiting

Conditions: Hairy Cell Leukemia

Interventions: Drug: Cladribine
Drug: Rituximab

First Posted Date: 2009-06-18

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 203

Registration Number: NCT00923013

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cladribine
Drug: temsirolimus
Biological: Filgrastim
Biological: Pegfilgrastim

First Posted Date: 2008-11-10

Last Posted Date: 2018-01-09

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 74

Registration Number: NCT00787969

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸
St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States

and more 141 locations

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Cladribine
Other: Laboratory Biomarker Analysis
Biological: Rituximab
Drug: Vorinostat

First Posted Date: 2008-10-02

Last Posted Date: 2017-12-11

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 57

Registration Number: NCT00764517

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

Oral Cladribine in Early Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine
Drug: Placebo
Drug: Rebif® new formulation (RNF)

First Posted Date: 2008-07-31

Last Posted Date: 2021-03-22

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 617

Registration Number: NCT00725985

Locations: 🇺🇸
Multiple Sclerosis Center Drive, Neurology Suite 701, Newport Beach, California, United States
🇺🇸
MS Center of Brevard MIMA Centry Research Associates, Melbourne, Florida, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 154 locations

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Phase 3

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Cladribine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-07-18

Last Posted Date: 2018-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 128

Registration Number: NCT00718549

Locations: 🇧🇾
City Clinical Hospital #9, Minsk, Belarus
🇵🇱
Szpital Uniwersytecki W Krakowie; Klinika Hematologii, Krakow, Poland
🇵🇱
Medical University, Independent Public Clinical Hospital; Dept. of Hematology, SPSK, Bialystok, Poland

and more 3 locations

Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Phase 2

Completed

Conditions: Lymphoma of Mucosa-Associated Lymphoid Tissue

Interventions: Drug: Rituximab
Drug: 2-CdA

First Posted Date: 2008-04-11

Last Posted Date: 2013-12-24

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 40

Registration Number: NCT00656812

Locations: 🇦🇹
Universitätsklinikum Graz, Graz, Austria
🇦🇹
Krankenhaus der Stadt Linz, Linz, Austria
🇦🇹
AKH Wien / Universitaetsklinik fuer Innere Medizin I, Vienna, Austria

and more 2 locations

CLARITY Extension Study

Phase 3

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Cladribine

First Posted Date: 2008-03-24

Last Posted Date: 2020-12-07

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 867

Registration Number: NCT00641537

Locations: 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
🇷🇺
Reseach Site, Saratov, Russian Federation

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: 2-CdA
Drug: Ara-C
Drug: G-CSF (Granulocyte colony-stimulating factor)

First Posted Date: 2007-06-06

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00483067

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Cladribine
Drug: Interferon-beta (IFN-beta)

First Posted Date: 2007-02-19

Last Posted Date: 2020-10-12

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 172

Registration Number: NCT00436826

Locations: 🇪🇸
Research Site, Seville, Spain
🇪🇸
Research site, Barcelona, Spain

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Phase 2

Recruiting

Conditions: Hairy Cell Leukemia
Recurrent Hairy Cell Leukemia

Interventions: Drug: Cladribine
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2006-12-18

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT00412594

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy